key: cord-0747220-v7vna65g
authors: Bloch, Michael J.
title: Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
date: 2020-07-21
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.06.003
sha: 260efc88ab1ecb59e02f4ab425c615aa528bfc51
doc_id: 747220
cord_uid: v7vna65g

[Figure: see text]

As seen in Figure 1 , similar to what was observed with the related SARS-CoVID-1 virus, the currently circulating SARS-CoVID-2 virus gains entry into cells through binding of its spike protein to the enzyme ACE2. ACE2 is a mostly membrane-bound carboxypeptidase with approximately 40% homology to the more commonly appreciated circulating ACE enzyme.

ACE2 is primarily responsible for degrading angiotensin II into angiotensin 1 to 7. The ACE2 enzyme is found in lung alveolar tissue, nasopharyngeal tissue, enterocytes, nervous tissue, vascular tissue, and the kidney (1)-all points of potential viral entry for SARS-CoVID-2.

The initial thinking regarding RAS-blocking agents and COVID-19 was that these drugs could have adverse effects due to up-regulation of ACE2 expression on cell surfaces leading to a greater number of potential sites of viral entry. Although ACE2 upregulation has been seen with RAS-blocking drugs in some animal models, reassuringly, in humans there is little evidence that these medications increase ACE2 levels, at least in circulation (2,3).

As our understanding of how SARS-CoVID-2 interacts with the RAS has grown, the theory that RASblocking agents may actually be beneficial has emerged. This hypothesis posits that COVID infection leads to imbalance between the potentially delete- Leaving the bench and heading to the bedside, we need to look for evidence as to which of these competing effects best fits the available data. 

Binding of COVID spike protein to ACE2 on cell surface leads to infection and a decrease in ACE2 available to degrade angiotensin II to angiotensin 1-7, tilting the balance toward adverse effects of angiotensin II type I receptor activation. ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; RAS ¼ renin-angiotensin syndrome; SARS-CoV-2 ¼ severe acute respiratory syndrome-coronavirus-2;TMPRSS2 ¼ transmembrane protease, serine 2. These shortcomings aside, it was encouraging to see that randomization to ramipril appears to have had no effect on susceptibility to infection or mortality, and this represents the only results from a randomized population we have available at the present time. Another interesting potential area of investigation is whether or not polymorphisms in ACE2 or other associated peptides may be partially responsible for the variable severity of clinical presentation and course with COVID-19 infection (11) . No significant association was identified between variants of ACE2 or TMPRSS2 (which primes the spike protein for binding with ACE2) in a recently published Italian cohort (12) , but further research is clearly needed.

Based on the limited data available to date, including this report from RASTAVI, the Heart Failure Society of America/American College of Cardiology/ American Heart Association statement remains as valid today as when it was published in the early stages of the pandemic: "recommend continuation of RAS antagonists for those patients who are currently prescribed such agents for indications for which these agents are known to be beneficial, such as heart failure, hypertension, or ischemic heart disease" (13) . We eagerly await the results of the planned randomized clinical trials of ARBs in COVID patients. Given the pathophysiological complexity of COVID-19 infection, it seems unlikely to me that RAS blockade will be a "silver bullet" that has a dramatically beneficial effect on clinical outcomes. But, unlike most other therapies being evaluated for this pandemic, ARBs are widely available, inexpensive, safe, and well-tolerated (14).

Even if they are shown to have only a modest clinical benefit, the overall impact could be substantial. This unfolding story certainly highlights that the RAS is much more complicated than the simple schema that we outline for our first-year medical students, and understanding it is integral not just to cardiovascular disease but other fundamental aspects of human physiology. 

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Circulating plasma concentrations of angiotensinconverting enzyme 2 in men and women with heart failure and effects of renin-angiotensinaldosterone inhibitors

Renin-angiotensin-aldosterone system blocker and the risk of Covid-19

Renin-angiotensin system inhibitors improve the clinical outcomes of covid-19 patients with hypertension

Reninangiotensin-aldosterone system inhibitors and risk of covid-19

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Ramipril in high-risk patients with COVID-19

Losartan for patients with COVID-19 requiring hospitalization

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

HFSA/ACC/ AHA statement addresses concerns re: using RAAS antagonists in COVID-19